Lv4
514 积分 2022-08-24 加入
A review of Eplontersen use in hereditary transthyretin amyloidosis
21天前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
5个月前
已完结
Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients
6个月前
已完结
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis
6个月前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
7个月前
已完结
Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer
7个月前
已完结
C1-Inhibitor: Structure, Functional Diversity and Therapeutic Development
8个月前
已完结
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
8个月前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
9个月前
已完结
皖公网安备34019202002308
